Bardia A, Kaklamani V, Wilks S, Weise A, et al. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol 2021 Jan 29:JCO2002272. doi: 10.1200/JCO.20.02272.
PMID: 33513026